#18. Novo Nordisk
Novo Allé
2880 Bagsværd
Denmark
Tel: (45) 4444-8888
Fax: (45) 4449-0555
www.novonordisk.com
| Headcount |
22,460 |
|
| Year Established |
1989 |
|
| Pharma Revenues |
$5,643 |
+16% |
| Total Revenues |
$5,643 |
+16% |
| Net Income |
$980 |
+17% |
| R&D Budget |
$850 |
+17% |
| Drugs Approved/Launched |
| Drug |
Indication |
| levemir |
type 1 and 2 diabetes |
| novomix 30, 50 and 70 |
type 1 and 2 diabetes |
| Drugs Pending Approval |
| Drug |
Indication |
| novomix |
type 1 and 2 diabetes |
| activelle |
hormone replacement therapy |
| Drugs in Phase IIB and Beyond |
| Drug |
Indication |
| liraglutide |
type 2 diabetes |
| aerx idms |
type 1 and 2 diabetes |
| novoseven |
intra-cerebral hemorrhages, bleeding |
| vagifem |
hormone replacement therapy |
| Top Selling Drugs |
| Drug |
Indication |
Sales |
(+/- %) |
| insulin and related products |
diabetes |
$2,509 |
4% |
| insulin analogs |
diabetes |
$1,219 |
62% |
| novoseven |
hemostasis management |
$847 |
16% |
| growth hormone therapy |
HGH deficiency |
$465 |
20% |
Account for 89% of total pharma sales, up from 88% in 2004
